|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-8-30
|
|
pubmed:abstractText |
High-dose ketoconazole (HDK) in combination with steroids has been recognized as an effective secondary hormonal therapy in androgen-independent prostate cancer (AIPC). However, HDK causes more severe adverse events than low-dose ketoconazole (LDK). To the authors' knowledge, relatively little is known regarding the efficacy of LDK in AIPC. The efficacy of LDK and of subsequent dose escalation from LDK to HDK was evaluated as secondary hormonal therapy in patients with AIPC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
975-81
|
|
pubmed:meshHeading |
pubmed-meshheading:16862573-Adult,
pubmed-meshheading:16862573-Aged,
pubmed-meshheading:16862573-Aged, 80 and over,
pubmed-meshheading:16862573-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16862573-Disease Progression,
pubmed-meshheading:16862573-Dose-Response Relationship, Drug,
pubmed-meshheading:16862573-Fatigue,
pubmed-meshheading:16862573-Humans,
pubmed-meshheading:16862573-Ketoconazole,
pubmed-meshheading:16862573-Male,
pubmed-meshheading:16862573-Middle Aged,
pubmed-meshheading:16862573-Neoplasms, Hormone-Dependent,
pubmed-meshheading:16862573-Prostate-Specific Antigen,
pubmed-meshheading:16862573-Prostatic Neoplasms,
pubmed-meshheading:16862573-Retrospective Studies,
pubmed-meshheading:16862573-Survival Analysis,
pubmed-meshheading:16862573-Tumor Markers, Biological
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
|
|
pubmed:affiliation |
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article
|
